At a glance
ClinicalIndex Comparison RecordN/ACompleted· 56 enrolled
Drug / intervention
Fractionated Stereotactic Radiosurgery (SRS) +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
In Brief
A clinical study evaluating Fractionated Stereotactic Radiosurgery (SRS) and Surgical resection for Brain Cancer and 3 related conditions. Completed, enrolled 56 participants across 1 site.
Detailed Summary
The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery (SRS) to treat brain metastases greater than 4.2 cm³ in size will be determined. This study investigates if increasing radiation dose improves outcome for patients without greater toxicity (side effects).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Cancer, Neoplasm Metastasis, Cancer of Brain and Nervous System, Metastatic Malignant Neoplasm to Brain
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedJun 2009
Primary CompletionOct 2017
Study CompletionDec 2019
TodayJul 2026
First PostedJun 25, 2009
Enrollment StartApr 1, 2009
Primary CompletionOct 31, 2017
Study CompletionDec 1, 2019
TodayJul 2, 2026
Enrollment to primary: 8.6 yearsPosted 17.0 years ago
Interventions
Fractionated Stereotactic Radiosurgery (SRS)radiation
Standard of care
Surgical resectionprocedure
Standard of care